Third in a Series

ABSTRACT

All patients with acute coronary syndromes and without obvious bleeding or acute cerebrovascular events are candidates for heparin therapy. This article is a review of the pharmacology of unfractionated and low-molecular-weight heparins, trials of heparin therapy in acute coronary syndromes, and recommendations for using these agents.